Le Lézard
Classified in: Health, Business
Subjects: LIC, TRI

ArcherDX, Celgene ink Worldwide Companion Diagnostic Agreement relating to Investigational Drug CC-122


BOULDER, Colo., Nov. 7, 2017 /PRNewswire/ -- ArcherDX announced today that it has signed an agreement to develop and commercialize a next-generation sequencing (NGS)-based oncology companion diagnostic (CDx) for Celgene's investigational drug CC-122 for indications in Diffuse Large B Cell Lymphoma (DLBCL). 

Archer(R) NGS assays by ArcherDX

Under the terms of the agreement, ArcherDX will use their patented Anchored Multiplex PCR (AMPtm) technology combined with the Illumina® MiSeqDxtm sequencing system and Archer® Analysis bioinformatics software to develop the CDx. The diagnostic assay is based on a proprietary gene expression signature developed by Celgene to identify DLBCL patients most likely to respond to CC-122, a cereblon-modulating agent currently under investigation in multiple disease settings. ArcherDX will retain the worldwide rights to commercialize the test and will pursue all filings with regional regulatory agencies.

"We look forward to this collaboration arrangement with Celgene to deliver on the promise of precision medicine in a disease indication with high unmet medical need," Jason Myers, CEO of ArcherDX, said in a statement.

About ArcherDX

ArcherDX addresses the bottlenecks associated with using NGS in oncogenic mutation detection by offering a robust platform for targeted sequencing. By combining proprietary AMPtm chemistry with easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance. Complemented by powerful bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery.  

ArcherDX is headquartered in Boulder, Colorado.  

 

SOURCE ArcherDX


These press releases may also interest you

at 08:05
Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed...

at 08:05
Lowell Farms Inc. (the "Company") , a California cannabis company with advanced distribution and production capabilities including extraction, manufacturing, sales and brand management, announces audited revenue and operating results for the fourth...

at 08:03
All Star Healthcare Solutions®, a full-service healthcare staffing company specializing in locum tenens and direct-hire opportunities for physicians, nurse practitioners, physician assistants, and certified registered nurse anesthetists, was named a...

at 08:03
NRx Pharmaceuticals, Inc. ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announces its anticipated financial results for the quarter and year ended December 31, 2023 and provides the following summary of...

at 08:01
Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose First Patient in Second Quarter of 2024 Received Safety Review Committee (SRC) Approval...

at 08:00
Breckenridge Brewery ("Breckenridge" or the "Brewery"), a pioneer in Colorado's craft beer scene, and a subsidiary of Tilray Brands, Inc. , announced today an exciting partnership with the Denver Nuggets to launch a celebratory beer the ?Championship...



News published on and distributed by: